<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913289</url>
  </required_header>
  <id_info>
    <org_study_id>675</org_study_id>
    <nct_id>NCT00913289</nct_id>
  </id_info>
  <brief_title>Liver Regeneration Therapy Using Autologous Adipose Tissue Derived Stromal Cells</brief_title>
  <official_title>Liver Regeneration Therapy Using Autologous Adipose Tissue Derived Stromal Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanazawa University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanazawa University</source>
  <brief_summary>
    <textblock>
      Mesenchymal stem cells have the capability to differentiate into hepatocytes and will be&#xD;
      useful for liver regeneration. Adipose tissue is relatively enriched with mesenchymal stem&#xD;
      cells compared to bone marrow tissue. In this trial, eligible liver cirrhosis patients will&#xD;
      receive autologous adipose tissue derived stromal cells which include such mesenchymal stem&#xD;
      cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The population of the liver cirrhosis patients is enormous in Japan and the only radical&#xD;
      treatment for them is liver transplantation. However, the number of giving donors is&#xD;
      extremely limited. Mesenchymal stem cells have been capable to differentiate into&#xD;
      mesodermal-lineage cells as well as endodermal-lineage cells such as hepatocytes. They reside&#xD;
      in the mesenchymal tissues such as bone marrows as well as adipose tissues. The latter&#xD;
      tissues are relatively enriched with mesenchymal stem cells compared to bone marrow cells. In&#xD;
      this study, the cirrhotic patients will receive autologous adipose tissue derived stromal&#xD;
      cells which contains substantial number of mesenchymal stem cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause harmful events</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>adipose tissue derived stromal cells</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adipose tissue derived stromal cells</intervention_name>
    <description>dosage</description>
    <arm_group_label>adipose tissue derived stromal cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver cirrhosis patients&#xD;
&#xD;
          -  Platelets count in peripheral blood: over 7.0x10^4/microliter&#xD;
&#xD;
          -  Serum creatinine: less than 1.5 mg/dl&#xD;
&#xD;
          -  Capable of understanding the features of this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Associated with risky gastroesophageal varices for bleeding&#xD;
&#xD;
          -  Severe portal hypertension&#xD;
&#xD;
          -  Complicated with severe heart failure&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Respiratory disease&#xD;
&#xD;
          -  Hematological disease&#xD;
&#xD;
          -  Coagulation disturbance and judged to be excluded by doctors&#xD;
&#xD;
          -  Associated with malignancy&#xD;
&#xD;
          -  Past history of the following:&#xD;
&#xD;
               -  malignancy&#xD;
&#xD;
               -  ischemic heart disease&#xD;
&#xD;
               -  cerebrovascular disease (cerebral infarction, cerebral hemorrhage)&#xD;
&#xD;
               -  decompensated status of liver cirrhosis&#xD;
&#xD;
          -  Pregnant, or possibility of pregnancy&#xD;
&#xD;
          -  Infected with HIV&#xD;
&#xD;
          -  Under mediation with adrenal corticoid steroid, anti-histamine drug&#xD;
&#xD;
          -  Anticipated with difficulty of follow-up observation&#xD;
&#xD;
          -  Anticipated with inconsistency of following the protocol&#xD;
&#xD;
          -  Addiction of alcohol drinking and unable to stop drinking&#xD;
&#xD;
          -  Other candidates who are judged to be not applicable to this study by doctors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuichi Kaneko, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Kanazawa University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>October 16, 2012</last_update_submitted>
  <last_update_submitted_qc>October 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanazawa University</investigator_affiliation>
    <investigator_full_name>Shuichi Kaneko</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Liver Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

